---
title: "U.S. stock night trading opening fluctuations: Worksport rose 10.43% in night trading; Livewire fell 10.14% in night trading"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291070975.md"
description: "Worksport rose 10.43% in after-hours trading; Livewire fell 10.14% in after-hours trading; Quhuo rose 23.59% in after-hours trading; Larimar Therapeutics rose 16.39% in after-hours trading; Viridian Therapeutics rose 15.20% in after-hours trading"
datetime: "2026-06-29T00:11:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291070975.md)
  - [en](https://longbridge.com/en/news/291070975.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291070975.md)
---

# U.S. stock night trading opening fluctuations: Worksport rose 10.43% in night trading; Livewire fell 10.14% in night trading

**U.S. Stock Night Market Opening Movements**

Worksport, up 10.43% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Livewire, down 10.14% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

**Top Gainers in the U.S. Night Market**

Quhuo, up 23.59% in the night market. No significant news recently; trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no\_news

Larimar Therapeutics, up 16.39% in the night market. Based on recent key news:

1.  On June 27, Larimar Therapeutics announced it would hold an investor webcast on June 29 to discuss the regulatory progress of its nomlabofusp clinical development program for Friedreich’s ataxia and data from its long-term open-label study. This news drove the stock price up.
    
2.  On June 26, the company issued a forward-looking statement emphasizing its management's views on future developments. Although these forecasts may not be accurate, they still triggered a positive market reaction.
    
3.  On June 27, as a biotechnology company focused on complex rare diseases, Larimar's latest clinical progress marks an important milestone in the treatment field, further boosting investor confidence. The biotechnology industry has been active recently, with significant capital inflows.
    

Viridian Therapeutics, up 15.20% in the night market. Based on recent key news:

1.  On June 26, Viridian Therapeutics announced that its drug Lumvoa for the treatment of thyroid eye disease received FDA approval and is now available on the market. This news drove the stock price up. Source: Reuters
    
2.  On June 26, Viridian Therapeutics stated that Lumvoa is the first approved drug for the treatment of thyroid eye disease, covering data for both active and chronic conditions. This news further enhanced market confidence. Source: Dow Jones Newswires
    
3.  On June 26, Viridian Therapeutics plans to submit a Biologics License Application (BLA) for a more convenient injectable treatment for thyroid eye disease in the first quarter of 2027, which may improve patient acceptance. Source: Company announcement. The market reacted positively to the new drug approval, with significant increases in trading volume

### Related Stocks

- [WKSP.US](https://longbridge.com/en/quote/WKSP.US.md)
- [LVWR.US](https://longbridge.com/en/quote/LVWR.US.md)
- [QH.US](https://longbridge.com/en/quote/QH.US.md)
- [LRMR.US](https://longbridge.com/en/quote/LRMR.US.md)
- [VRDN.US](https://longbridge.com/en/quote/VRDN.US.md)

## Related News & Research

- [LiveWire director William L. Cornog sells 216 shares for $486](https://longbridge.com/en/news/294866700.md)
- [LiveWire hosts S4 Honcho Party with Gas Monkey Garage at Sturgis rally](https://longbridge.com/en/news/294821192.md)
- [Aaron Rosenberg Implements A Sell Strategy: Offloads $361K In BeOne Medicines Stock](https://longbridge.com/en/news/295122313.md)
- [BUZZ-Braveheart Bio poised to surge in New York debut after upsized $383 million IPO](https://longbridge.com/en/news/295120870.md)
- [BeOne Medicines teams with Revolution Medicines on RAS cancer drug development, Asia rights deal](https://longbridge.com/en/news/295388146.md)